tradmap

SCLX Scilex Holding Co

$7.11 +0.78%

Healthcare · Biological Products, (No Diagnostic Substances)

Scilex Holding Co (SCLX) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $60 million. Shares last traded at $7.11, 79.3% below their 52-week high. Over the past year the stock is up 54.9%. Net profit margin is -1236.4%, below the peer median of 6.3%. Revenue declined 46.5% year over year.

Market Cap
$60M
Shares Out
8.5M
EPS (TTM)
$-50.10
P/E Ratio
P/S Ratio
2.00
P/B Ratio
Dividend / Share
Dividend Yield
52-Week High
$34.27
52-Week Low
$4.62
Volume
2,067
Avg Vol (3m)
1,966.571

Performance

1W
-18.74%
1M
+18.11%
3M
-11.68%
6M
-54.34%
YTD
-45.20%
1Y
+54.90%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
48.32
SMA (50)
$7.35
SMA (200)
$12.77
Price vs SMA50
-3.30%
Price vs SMA200
-44.32%
ATR (14)
$0.90

Financials

Revenue
$30M
Net Income
$-374M
Gross Margin
415.8%
Operating Margin
-1143.7%
Net Margin
-1236.4%
Return on Equity
150.1%
Return on Assets
-127.4%
Current Ratio
0.08
Debt / Equity
0.00
Revenue Growth (YoY)
-46.5%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-6.28 2026-05-20
FY 2025 $-36.48 2026-04-10
Q3 2025 $-31.88 2025-11-14
Q2 2025 $-9.68 2025-08-13
Q1 2026 $-2.26 2026-05-20
FY 2025 $-8.05 2026-04-10

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

SCLX vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers
2.00 / 5.21 med
-62% discount
Net margin vs peers
-1236.4% / 6.3% med
below median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.